Trial
NCT00864513
Study of Pemetrexed for Second-Line Pancreas Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Georgetown University
Collaborators
Eli Lilly and Company
Condition
Pancreas Cancer
Intervention
pemetrexed
Why stopped
At interim analysis the study did not meet the response criteria to continue
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-08